--- title: "Weekly Recap | WUXI BIO +0.7%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/298092178.md" description: "WuXi Biologics rose 0.7% this week to close at HK$49.18, up from the previous close of HK$48.84. The Hang Seng Index gained 0.33% over the same period, so WuXi Biologics outperformed the benchmark by about 0.37 percentage points. The four-day week showed a pull-back after an intraday spike: Monday opened at HK$48.86, hit a weekly low of HK$48.18, and closed at HK$49.48. Tuesday drifted to HK$49.24. Wednesday saw heavy volume push the stock to a weekly high of HK$51." datetime: "2026-09-05T05:12:24.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298092178.md) - [en](https://longbridge.com/en/news/298092178.md) - [zh-HK](https://longbridge.com/zh-HK/news/298092178.md) generator: "portal-rs" --- # Weekly Recap | WUXI BIO +0.7%, most brokers rate it buy ## The Week WuXi Biologics rose 0.7% this week to close at HK$49.18, up from the previous close of HK$48.84. The Hang Seng Index gained 0.33% over the same period, so WuXi Biologics outperformed the benchmark by about 0.37 percentage points. The four-day week showed a pull-back after an intraday spike: Monday opened at HK$48.86, hit a weekly low of HK$48.18, and closed at HK$49.48. Tuesday drifted to HK$49.24. Wednesday saw heavy volume push the stock to a weekly high of HK$51.35 before closing at HK$50.70. Thursday opened near the high but slid back to finish at HK$49.18, nearly erasing Wednesday’s gain. Weekly amplitude was 6.49%, and average daily volume ran about 3.6% above the 20-week median. ## Key Events The main company-specific activity this week was a small increase in share capital from option exercises. On 2, 3 and 4 September, WuXi Biologics filed next-day disclosure returns with the HKEX reporting new share issuance of 1.528m, 2.424m and 3.200m shares respectively. Together these three batches added roughly 7.15m shares, a negligible proportion of the total float, with limited linkage to the share-price moves. Early in the week pharma sentiment was soft: on 31 August WuXi Biologics and BeiGene fell on unusual trading, and WuXi Biologics dropped more than 3% intraday. The same day, BioNTech’s decision to pause an mRNA trial dragged HK-listed vaccine makers lower, led by CanSino. On 3 September pharma stocks rallied, helping the Hang Seng edge up 6 points by midday, and WuXi Biologics touched its weekly high before retreating on Thursday. Overall, the company released no product, earnings or regulatory news this week; price action was driven mostly by sector sentiment and market rhythm. ## Analyst Ratings As of this week, 28 analysts cover WuXi Biologics: 18 rate it buy, 5 overweight, and 5 hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target price is HK$57.34, about 16.6% above the latest price of HK$49.18. The target-price range is wide, from HK$30.83 at the low end to HK$79.06 at the high end, suggesting meaningful dispersion in valuation views. WuXi Biologics ranks first among 12 companies in the life sciences tools and services industry, where the average coverage is 11 analysts and the median is 9. ## The Week Ahead The company has no disclosed earnings or major event calendar next week. On the macro side, Hong Kong’s unemployment rate is due on 17 September, with a previous reading of 3.7; the composite CPI is due on 23 September, with a previous reading of 1.7. Hong Kong pharma stocks have shown elevated sensitivity to macro data and global healthcare news, so these prints could indirectly sway sector risk appetite. The run of option-related share issuances this week also leaves open the question of whether any larger capital or business announcement follows. ## In Short WuXi Biologics finished the week with a modest 0.7% gain after an intraweek run toward HK$51 and a subsequent pull-back. The analyst picture leans supportive: 23 of 28 brokers rate it buy or overweight, and the consensus target sits 16.6% above spot. Yet the latest trading day showed split money flows, with large-lot accounts as net sellers while medium and small lots were net buyers, and the target-price spread from HK$30 to HK$79 points to weak consensus on valuation. The tension going forward is between a buy-rated consensus and a relatively rich valuation at about 3.7x book and 35x earnings against a market that remains quick to rotate in and out of pharma. What matters next is whether sector risk appetite holds after the macro prints, and whether WuXi Biologics delivers anything more substantive than the small option-driven capital changes seen this week. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) ## Related News & Research - [Transcenta licenses HiCB bioprocessing technology to WuXi Biologics for RMB 10 million upfront](https://longbridge.com/en/news/298454168.md) - [WuXi Biologics files HKEX next-day disclosure return, issues 1,804,090 new shares](https://longbridge.com/en/news/298215084.md) - [Shein expands U.S. fulfillment network with 737,000-square-foot Indiana warehouse](https://longbridge.com/en/news/298971911.md) - [G Sachs: China CRO/CDMO Industry Recovery Pace Clear; Positive on WUXI Series, PHARMARON, ASYMCHEM, TIGERMED and GENSCRIPT BIO](https://longbridge.com/en/news/298712241.md) - [Citi: AKESO HARMONi-2 Overall Survival Superiority Reinforces ivonescimab's Differentiated Advantages](https://longbridge.com/en/news/298865257.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**